Loading patent…
AssigneeAventis Pharma Deutschland GmbH
InventorsPaulus Wohlfart, Teri Suzuki, Ramalinga M. Dharanipragada, Alena Safarova, Armin Walser, Hartmut Strobel
Estimating the term…
The present invention relates to the method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I) to the said mammal. The compound (I) can be used for the therapy and prophylaxis of cardiovascular diseases like stable and unstable angina pectoris, Prinzmetal angina (spasm), acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease PAOD, atherosclerosis, restenosis, endothelial damage after PTCA, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, and the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives, the therapy and prophylaxis of diabetes and diabetes complications (nephropathy, retinopathy), angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, restricted memory performance or a restricted ability to learn.
A pharmaceutical preparation for the stimulation of the expression of endothelial NO-synthase, which pharmaceutical preparation comprises an effective amount of 4-fluoro-N-indan-2-yl benzamide, at least one other pharmaceutically active compound, and a pharmaceutically acceptable carrier.
A pharmaceutical preparation for the treatment of a mammal suffering from a disease chosen from stable and unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes and diabetes complications, nephropathy and retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, and a restricted ability to learn, which pharmaceutical preparation comprises an effective amount of 4-fluoro-N-indan-2-yl benzamide, at least one other pharmaceutically active compound, and a pharmaceutically acceptable carrier.
A pharmaceutical preparation for the treatment of a mammal suffering from a cardiovascular disease, which pharmaceutical preparation comprises an effective amount of 4-fluoro-N-indan-2-yl benzamide, at least one other pharmaceutically active compound, and a pharmaceutically acceptable carrier.
A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)
A method of treating a mammal suffering from a disease chosen from stable and unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes and diabetes complications, nephropathy and retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, and a restricted ability to learn, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)
A method of treating a mammal suffering from a cardiovascular disease, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)
A method of treating a human suffering from a disease chosen from endothelial dysfunction, hypertension, coronary heart disease, stable angina pectoris, diabetes complications and atherosclerosis, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)
A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering a pharmaceutical preparation comprising an effective amount of 4-fluoro-N-indan-2-yl benzamide and a pharmaceutically acceptable carrier.
A method of stimulating the expression of endothelial NO-synthase in a mammal for the treatment of the mammal suffering from a disease chosen from stable and unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes and diabetes complications, nephropathy and retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, and a restricted ability to learn, which method comprises administering to the mammal a pharmaceutical preparation comprising an effective amount of 4-fluoro-N-indan-2-yl benzamide and a pharmaceutically acceptable carrier.
A method of stimulating the expression of endothelial NO-synthase in a mammal for the treatment of the mammal suffering from a cardiovascular disease, which method comprises administering to the mammal a pharmaceutical preparation comprising an effective amount of 4-fluoro-N-indan-2-yl benzamide and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.